Table 2.
Secondary care diagnostic interval (SCDI) & regression results: Lung cancer.
| n (%) | SCDI (days) centiles |
Unadjusted | Adjusted |
|||||
|---|---|---|---|---|---|---|---|---|
| 25th | 50th | 75th | 90th | OR (95% CI) | OR (95% CI) | |||
| Total cohort | 71 361 | 15 | 36 | 85 | 144 | |||
| Age group | p < 0.0001 | |||||||
| <25 | 35 (0.1) | 8 | 24 | 75 | 123 | 0.79 (0.40-1.54) | 0.67 (0.29-1.54) | |
| 25-44 | 720 (1.0) | 12 | 29.5 | 72 | 134.5 | 0.81 (0.69-0.94) | 0.86 (0.71-1.03) | |
| 45-49 | 1 104 (1.6) | 13 | 30 | 66 | 126 | 0.77 (0.68-0.88) | 0.90 (0.77-1.04) | |
| 50-54 | 2 354 (3.3) | 14 | 31 | 73 | 133 | 0.81 (0.74-0.89) | 0.91 (0.82-1.02) | |
| 55-59 | 4 279 (6.0) | 16 | 34 | 76 | 136 | 0.92 (0.85-0.99) | 0.98 (0.90-1.07) | |
| 60-64 | 7 335 (10.3) | 17 | 35 | 79 | 139 | Reference | ||
| 65-69 | 11 449 (16.0) | 17 | 36 | 84 | 141 | 1.02 (0.96-1.08) | 1.01 (0.94-1.08) | |
| 70-74 | 12 445 (17.4) | 18 | 40 | 88 | 147 | 1.16 (1.09-1.22) | 1.15 (1.07-1.23) | |
| 75-79 | 12 355 (17.3) | 16 | 41 | 92 | 150 | 1.18 (1.11-1.25) | 1.17 (1.09-1.25) | |
| 80-84 | 10 055 (14.1) | 14 | 38 | 93 | 149 | 1.11 (1.05-1.18) | 1.18 (1.10-1.27) | |
| ≥85 | 9 230 (12.9) | 7 | 28 | 81 | 141 | 0.82 (0.77-0.88) | 1.10 (1.02-1.19) | |
| Sex | p = 0.9836 | |||||||
| Male | 38 149 (53.5) | 15 | 36 | 85 | 144 | Reference | ||
| Female | 33 212 (46.5) | 14 | 36 | 85 | 144 | 0.98 (0.95-1.01) | 1.00 (0.97-1.04) | |
| Ethnicity | p = 0.0002 | |||||||
| White | 65 763 (92.2) | 15 | 37 | 86 | 145 | Reference | ||
| Black | 648 (0.9) | 13 | 33 | 86 | 147 | 0.86 (0.74-1.01) | 0.94 (0.78-1.13) | |
| Asian | 984 (1.4) | 16 | 42 | 99 | 153 | 1.15 (1.01-1.31) | 1.04 (0.89-1.21) | |
| Mixed & other | 891 (1.3) | 13 | 31 | 75 | 133 | 0.81 (0.71-0.92) | 0.90 (0.77-1.06) | |
| Not known | 3 075 (4.3) | 9 | 25 | 61 | 128 | 0.60 (0.56-0.65) | 0.82 (0.75-0.89) | |
| Deprivation quintile | p=0.2647 | |||||||
| 1 - least deprived | 10 172 (14.3) | 16 | 36 | 85 | 143 | Reference | ||
| 2 | 12 796 (17.9) | 16 | 36 | 84 | 146 | 0.99 (0.94-1.05) | 1.02 (0.96-1.08) | |
| 3 | 14 039 (19.7) | 15 | 36 | 85 | 143 | 0.98 (0.94-1.04) | 1.04 (0.97-1.10) | |
| 4 | 15 823 (22.2) | 15 | 36 | 85 | 144 | 1.00 (0.95-1.05) | 1.06 (1.00-1.13) | |
| 5 - most deprived | 18 531 (26.0) | 14 | 36 | 86 | 146 | 0.97 (0.92-1.02) | 1.02 (0.96-1.08) | |
| Stage | p < 0.0001 | |||||||
| 1&2 | 16 521 (23.2) | 34 | 70 | 123 | 162 | Reference | ||
| 3A | 8 021 (11.2) | 22 | 42 | 88 | 143 | 0.48 (0.45-0.50) | 0.53 (0.50-0.57) | |
| 3B&4 | 41 506 (58.2) | 11 | 27 | 61 | 124 | 0.25 (0.24-0.26) | 0.38 (0.37-0.40) | |
| unknown/other | 5 313 (7.5) | 8 | 38 | 104 | 155 | 0.39 (0.37-0.42) | 0.70 (0.65-0.75) | |
| Diagnostic route | p < 0.0001 | |||||||
| Emergency Presentation | 24 906 (34.9) | 4 | 14 | 52 | 126 | 0.48 (0.46-0.50) | 0.36 (0.34-0.37) | |
| GP Referral (routine) | 16 657 (23.3) | 32 | 69 | 126 | 163 | 2.59 (2.48-2.71) | 2.56 (2.43-2.69) | |
| Two Week Wait | 20 415 (28.6) | 22 | 35 | 63 | 107 | Reference | ||
| Inpatient Elective | 1 240 (1.7) | 9 | 18 | 43 | 107 | 0.43 (0.37-0.48) | 0.37 (0.32-0.43) | |
| Other Outpatient | 8 143 (11.4) | 30 | 66 | 122 | 161 | 2.38 (2.25-2.51) | 2.00 (1.88-2.12) | |
| Charlson comorbidity score | p < 0.0001 | |||||||
| 0 | 49 079 (68.8) | 14 | 31 | 67 | 121 | Reference | ||
| 1 | 10 110 (14.2) | 20 | 53 | 116 | 161 | 1.91 (1.83-2.00) | 1.75 (1.66-1.84) | |
| 2 | 5 982 (8.4) | 22 | 63 | 126 | 162 | 2.25 (2.12-2.38) | 2.09 (1.95-2.23) | |
| 3+ | 6 190 (8.7) | 22 | 75 | 139 | 169 | 2.51 (2.37-2.65) | 2.46 (2.30-2.62) | |
| CXR and CT count | p < 0.0001 | |||||||
| 0 | 4 766 (6.7) | 5 | 15 | 41 | 96 | 0.60 (0.56-0.65) | 0.55 (0.50-0.60) | |
| 1 | 10 540 (14.8) | 7 | 25 | 58 | 114 | Reference | ||
| 2 | 27 295 (38.3) | 12 | 26 | 52 | 110 | 0.92 (0.88-0.96) | 0.98 (0.93-1.03) | |
| 3+ | 28 760 (40.3) | 31 | 67 | 123 | 161 | 3.84 (3.66-4.02) | 5.25 (4.97-5.54) | |
| Additional diagnostics* | P < 0.0001 | |||||||
| No | 60 848 (85.3) | 13 | 32 | 79 | 141 | Reference | ||
| Yes | 10 513 (14.7) | 34 | 61 | 108 | 155 | 2.99 (2.85-3.12) | 2.12 (2.01-2.24) | |
*
Lung cancer additional tests in 6 months before diagnosis- PET, SPECT, Bronchoscopy, EBUS.